{"name": "NicOx",
 "permalink": "nicox",
 "crunchbase_url": "http://www.crunchbase.com/company/nicox",
 "homepage_url": "http://www.nicox.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "nicox@nicox.com",
 "phone_number": "33 4 97 24 53 00",
 "description": "",
 "created_at": "Thu Nov 19 02:41:37 UTC 2009",
 "updated_at": "Wed Mar 14 00:23:17 UTC 2012",
 "overview": "\u003Cp\u003ENicOx S.A., a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company\u00e2\u20ac\u2122s primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company\u00e2\u20ac\u2122s product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck \u0026amp; Co., Inc. for the development of new antihypertensive drugs using NicOx\u00e2\u20ac\u2122 nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[103,
       74],
      "assets/images/resized/0006/6748/66748v1-max-150x150.jpg"],
     [[103,
       74],
      "assets/images/resized/0006/6748/66748v1-max-250x250.jpg"],
     [[103,
       74],
      "assets/images/resized/0006/6748/66748v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman \u0026 CEO",
    "person":
     {"first_name": "Michele",
      "last_name": "GARUFIc",
      "permalink": "michele-garufic",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Eric",
      "last_name": "CASTALDI",
      "permalink": "eric-castaldi",
      "image": null}},
   {"is_past": false,
    "title": "Director",
    "person":
     {"first_name": "Vaughn",
      "last_name": "Kailian",
      "permalink": "vaughn-kailian",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$149M",
 "funding_rounds":
  [{"round_code": "post_ipo_equity",
    "source_url": "http://www.fiercebiotech.com/story/nicox-raising-149m-back-blockbuster-launch/2009-11-18?utm_medium=rss\u0026utm_source=rss\u0026cmp-id=OTC-RSS-FB0",
    "source_description": "NicOx raising $149M to back blockbuster launch",
    "raised_amount": 149000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 11,
    "funded_day": 18,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Les Taissounieres-1681 Route des Dolines-Bat HB4",
    "address2": "BP 313 Cedex",
    "zip_code": "06906",
    "city": "Sophia Antipolis",
    "state_code": null,
    "country_code": "FRA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "NicOx gains new partner on glaucoma program",
    "stoned_year": 2010,
    "stoned_month": 3,
    "stoned_day": 3,
    "source_url": "http://www.fiercebiotech.com/story/nicox-gains-new-partner-glaucoma-program/2010-03-03?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "NicOx gains new partner on glaucoma program",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "NicOx",
      "permalink": "nicox"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": 2000,
   "pub_month": 12,
   "pub_day": 29,
   "stock_symbol": "EPA:COX"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}